965 results on '"Serebruany, Victor L."'
Search Results
2. Impact of Bleeding on Myocardial Infarction, Stroke, and Death During 12 Months Dual Antiplatelet Therapy After Acute Coronary Syndrome
3. Thienopyridine reloading in clopidogrel-loaded patients undergoing percutaneous coronary interventions: The PRAISE study
4. All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System
5. Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year
6. Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30 day mortality in patients with ST-elevated myocardial infarction
7. Survival After Solid Cancers in Antithrombotic Trials
8. Body Mass Index and Plasma P-Selectin before Coronary Stenting Predict High Residual Platelet Reactivity at 6 Months on Dual Antiplatelet Therapy
9. Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS)
10. Cangrelor infusion is associated with an increased risk for bleeding: Meta-analysis of randomized trials
11. Incidence and Causes for Early Ticagrelor Discontinuation: A “Real-World” Dutch Registry Experience
12. Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
13. Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook
14. Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar
15. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis
16. Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up
17. Aspirin ‘Resistanceʼ: Impact on No-Reflow, Platelet and Inflammatory Biomarkers in Diabetics after ST-Segment Elevation Myocardial Infarction
18. Impact of Valve Surgery on Serum Osteopontin Levels in Patients with Mitral Regurgitation
19. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: A randomized, single-blind, 30-day trial
20. Stability validation of paraformaldehyde-fixed samples for the assessment of the platelet PECAM-1, P-selectin, and PAR-1 thrombin receptor by flow cytometry
21. Switching from Generic to Brand Clopidogrel in Male Patients after ST-Elevated Myocardial Infarction
22. Angiographic Outcomes Contradict Platelet Data in the PLATO Trial: Confusion over Official Trial Substudies
23. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study
24. Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease
25. The FDA and PLATO Investigators death lists: Call for a match
26. Dyspnea and Reversibility of Antiplatelet Agents: Ticagrelor, Elinogrel, Cangrelor, and Beyond
27. The action of dipyridamole to prevent thrombosis: Practical implications for the treatment and prevention of stroke
28. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial
29. Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease
30. Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial
31. Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial
32. Noncompliance in cardiovascular clinical trials
33. Introduction
34. Conclusion
35. Changes of Ticagrelor Formulary Tiers in the USA: Targeting Private Insurance Providers away from Government-Funded Plans
36. Letter by Serebruany and DiNicolantonio Regarding Article, “Ticagrelor in Patients With Acute Coronary Syndromes and Stroke: Interpretation of Subgroups in Clinical Trials”
37. Gastrointestinal Adverse Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive
38. The Bleeding Risk during Warfarin Therapy Is Associated with the Number of Variant Alleles of CYP2C9 and VKORC1 Genes
39. The Effects of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Platelet and Inflammatory Biomarkers in Patients with Metabolic Syndrome
40. Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes
41. Unclassified Pleomorphic and Spindle Cell Pulmonary Neoplasm with Brain Metastases after Prasugrel
42. Exploring the Ticagrelor-Statin Interplay in the PLATO Trial
43. Effect of Eptifibatide for Acute Coronary Syndromes: Rapid Versus Late Administration—Therapeutic Yield on Platelets (The EARLY Platelet Substudy)
44. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: The Plavix use for treatment of congestive heart failure (PLUTO-CHF) trial
45. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the roxifiban oral compound kinetics evaluation trial-I (ROCKET-I platelet substudy)
46. Effect of tenecteplace versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction : The assessment of the safety and efficacy of a new thrombolytic agent (ASSENT-2) platelet substudy
47. Platelet activation in patients with congestive heart failure: Do we have enough evidence to consider clopidogrel?
48. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The palvix reduction of new thrombus occurrence (PRONTO) trial
49. Comparing Ticagrelor Versus Clopidogrel in Patients With a History of Cerebrovascular Disease: A Net Clinical Harm?
50. Aspirin in Patients with Coronary Artery Disease: Is it Simply Irresistible?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.